



The impact of COVID-19

2019 was a good year for the charity, with exciting news from our research and fundraising teams. 2020, the charity's 15th anniversary year, was shaping up to be a milestone year, with ground-breaking and promising research being underpinned by growing income.

And then the unimaginable happened.

The impact of COVID-19 has been wide-ranging for The Cure Parkinson's Trust, just as it has been for the Parkinson's community and the wider research community.

Our plans to build on the work of 2019 have changed significantly. Research and trials are delayed and many of our fundraising plans are cancelled or postponed. Our work will restart as quickly as COVID-19 allows, but in the meantime we are working behind the scenes with our science and funding partners to ensure we can resume our vital work as soon as possible.

Whilst we anticipate delays to our research, you can expect no change in our commitment to find a cure for Parkinson's. We are more determined than ever to meet our goal.

To stay in touch with our latest news as we emerge from COVID-19, please sign up to our monthly e-news www.cureparkinsons.org.uk/forms/permissions

If you are able to donate, we would be hugely grateful for any contribution you can make. This will help ensure our research resumes as quickly as COVID-19 allows. Please use the donation form in the centre of this Annual Review. Alternatively, you can donate on our website at www.cureparkinsons.org.uk/donation

Slow, stop, reverse... *for a cure*

William Cook, CEO of The Cure Parkinson's Trust (pictured right) and Charlie Ralph, Chair of the Board of Trustees (pictured left)



Slow, stop, reverse.

These three words have defined The Cure Parkinson's Trust for 15 years. In 15 years, this charity has grown from a group of four individuals, with a vision but no office, to become an international catalyst for the search for a cure. We are very proud to lead a charity that has changed the face of Parkinson's research.

We are enabling and encouraging the finest neuroscientists and neurologists around the world to prioritise the most promising pre-existing and new drugs for clinical trial against Parkinson's. This work is supported through the relationships we have with global pharma and biotech companies.

Our International Linked Clinical Trial (iLCT) programme continues to go from strength to strength. Our outstanding iLCT committee's focus on repurposing drugs, drugs that have the potential to be available to treat Parkinson's in five years, reflects the urgency that we feel about delivering a cure. 14 of the drugs prioritised by our outstanding iLCT committee are progressing through or close to clinical trials, many of which we fund or co-fund. Each has the potential to achieve our goal of slowing, stopping or reversing Parkinson's.

However, we receive no statutory funding. All our work is paid for by funding partners and donors. We are pleased that, as in 2018, our income in 2019 exceeded £3 million, driven by the generosity of our supporters. We are hugely grateful to you all.

You have enabled us to support the iLCT committee to prioritise the next generation of drugs, and to fund sub-studies, trials and extensions for several iLCT prioritised drugs including exenatide, nortriptyline, ambroxol, UDCA, simvastatin and liraglutide. Exenatide and ambroxol are moving forward to their next stage trials, and we will see results from some of the other trials soon.

Despite the challenging times we all currently face, we have the ambition to grow, to accelerate the work that will lead to a cure. In 2019 we announced a strengthening of the partnership we have with Van Andel Institute (VAI) and their pioneering team based in Michigan, US; just one example of our international collaboration. This partnership represents a \$4.5m joint commitment to Parkinson's research over the next three years. This is a significant sum, but is only a portion of what we need to raise to slow, stop or reverse Parkinson's. In that context we are delighted to welcome our new Director of Fundraising &

Marketing, Rick Lay, a committed fundraiser with a passion for our cause.

More widely, we are hugely grateful for all the support we have had from our committed volunteers. From advocates helping to shape our research to scientists and clinicians serving on our decision-making committees, from fundraisers raising both money and awareness to trustees responsible for charity-wide best practice, thank you.

Finally, a special "thank you" to Rick Cawdron, who served the charity as a trustee from 2008 until December 2019, and "welcome" to our newest trustee, David Tyndall. As Chair of our Finance Committee, Rick has overseen our growth for over 10 years, and we are grateful for his calm and knowledgeable service.

2020 brings economic and social uncertainty across the world but this charity remains committed and focussed on our goal: a cure for Parkinson's.

To keep up-to-date with CPT's work to find a cure for Parkinson's, please visit www.cureparkinsons.org.uk

Linked Clinical Trials... *for a cure*

Eight years on from its launch in 2012, the International Linked Clinical Trials (iLCT) programme, **Dr Simon Stott** updates on the developments within the programme which continues to go from strength to strength.



Even given the COVID-19 crisis we anticipate that 2020 will be an important year for The Cure Parkinson's Trust (CPT) with regards to our International Linked Clinical Trials (iLCT) programme. Not only are we witnessing the start of our first large Phase III clinical trial, but we also have the completion of two ongoing Phase II clinical trials, the continuation of numerous additional studies, and the start of multiple new clinical trials. Remarkable accomplishments for an initiative that began just eight years ago.

The first drug to be prioritised by the iLCT committee of Parkinson's experts was a diabetes medication called exenatide. Preclinical data in models of Parkinson's indicated that this treatment was a very compelling candidate for drug re-purposing, and subsequent results from clinical trials have given rise to one of the most exciting developments in the field of Parkinson's research. CPT is extremely proud to see exenatide entering Phase III – the crucial final step – clinical testing in 2020.

Another re-purposed drug that is being prepared for Phase III testing is ambroxol. This is a respiratory medication that has exhibited useful properties involving a specific Parkinson's-associated protein. In 2020, the results of a Phase II clinical trial demonstrated that this drug is safe in people with

Parkinson's (PwP) and having positive effects in the brain. CPT has recently approved the next step – a dose evaluating study - in the development of this potential Parkinson's treatment.

In 2020, we will also see the initiation of additional clinical trials being supported by CPT, such as the azathioprine sub study for Parkinson's. Azathioprine is a medication that is used to reduce the activity of the immune system. There is considerable evidence to suggest that people with Parkinson's have a heightened level of activity in their immune system. By reducing this activity, researchers hope to slow down the progression of the condition.

CPT recently announced a new three-year co-funding agreement with the Van Andel Institute (VAI) that pledges USD \$4.5 million to Parkinson's research, strengthening an already long-standing partnership. This funding will support drugs prioritised through the iLCT initiative.

Since its inception in 2012, CPT's and VAI's involvement has ensured that each year the iLCT initiative goes from strength to strength as progressively more clinical trials of potentially disease-modifying drugs are launched in more countries within the programme.

Currently, 14 trials of drugs evaluated by the committee are underway and seven trials have been completed. In addition, a further 10 trials are in the planning stages. To date, iLCT has included more than 2500 trial participants.

Professor Patrik Brundin, Chair of the International Linked Clinical Trials committee and Director of the Center for Neurodegenerative Science at VAI said:

"We are thrilled to continue our long-standing collaboration with The Cure Parkinson's Trust on the iLCT initiative and look forward to expanding our program to evaluate additional promising medications in the coming years. We are especially grateful to the trial participants, without whom this critical work would not be possible. I am immensely hopeful that, together, we will find a way to slow or stop Parkinson's progression."

You can read more about the iLCT programme by visiting our website at www.cureparkinsons.org.uk/clinicaltrials

Looking forward... *for a cure*

Dr Richard Wyse, CPT Director of Research & Development, looks to the future of iLCT and CPT's research programmes.

In its search of a definitive cure, CPT continues globally to fund pre-clinical research in academic and commercial laboratories, and clinical research in many hospitals around the world. As well as our involvement in regenerative medicine (both in clinical trials testing cellular replacement, and growth factor infusions), we continue to facilitate clinical trials in patients with Parkinson's involving a range of different drugs each of which demonstrates compelling biochemical reasons for us to believe they hold strong potential for slowing, stopping or reversing the year-on-year neurodegeneration that characterises the condition.

Some of these drugs target the pathological changes inherent of the disease, some improve the energy requirements of cells that are central to Parkinson's (as this is known to be compromised). Other drugs we have in clinical trials crucially aim to reduce the neuroinflammation that tends to accompany the disease, while others increase the removal of waste products from the cells (which is known to be attenuated in Parkinson's).

We believe that drug combinations simultaneously tackling each of these cellular processes are likely to be more successful than any single drug approach. Drug combinations are commonly used in treating cancer patients, but in other conditions, the national drug

regulators – for safety reasons - prefer single therapies to be tested first, separately, before allowing them to be combined in a clinical trial. As our many current clinical trials deliver their results over the next year or so, we will then immediately be looking to start trials involving two to three drugs, each already known to be safe – with the expectation that various of these combinations will offer greater therapeutic benefit than any of our current monotherapy trials. With this thought in mind, in 2021 we hope to start our first drug combination trial in Parkinson's patients under our unique iLCT initiative.



Dr Richard Wyse (left) with Professor Patrik Brundin (right), Chair of the iLCT committee, at the annual iLCT meeting at VAI, Grand Rapids, Michigan

Ambroxol Update

In late 2014, the iLCT committee prioritised ambroxol, a commonly used medication in Europe for the treatment of respiratory diseases, for clinical evaluation in Parkinson's. In early 2020, the results of a phase II clinical trial showed ambroxol to be safe and well tolerated with no reported adverse events during the study. The drug was also found to cross the blood brain barrier and it achieved a good level of penetrance into the brain with a 35% increase overall in GCase protein levels found in participants' cerebrospinal fluid.

In September 2019, CPT hosted a meeting with Parkinson's drug development experts Professors Tom Foltynie, Karl Kiebertz, Werner Poewe and Olivier Rascol who recommended that the next most important step towards a formal efficacy study for disease modification was a dose-ranging study. A range of doses will be assessed in a study involving 40 people with Parkinson's, half of whom will have GBA* Parkinson's.

In parallel, we have met with regulators to ensure we have identified all their requirements to move ambroxol forward. Whilst this study is ongoing, we will be working with the investigators to design and raise the funds needed for a future phase III study.

** Mutations in the glucocerebrosidase gene (GBA) encoding are associated with an increased susceptibility to Parkinson's disease.*

To donate to the International Linked Clinical Trials programme, please visit www.cureparkinsons.org.uk/iLCT

Research... *for a cure*

In 2019, **Professor Alasdair Coles, Chair of CPT's Research Committee**, took up the mantle from Dr John Scadding who had skilfully guided the work of the committee for 10 years, shaping CPT's research strategy and direction for funding. As an academic neurologist in Cambridge, Dr Coles' primary research interest is in the immunology and treatment of multiple sclerosis. He has first-hand experience of supporting a drug through clinical trials and the regulatory processes.



It has been a complete pleasure to chair CPT's research committee as its purpose is so clear and the dedicated members of the committee scrutinize proposals with such consideration to ensure each recommended project matches the charity's drive for a cure.

In August I joined the CPT team at the annual International Linked Clinical Trials meeting in Grand Rapids Michigan, as we have been undertaking a similar drug prioritisation effort in MS as part of a plan to introduce a new way of speeding up the clinical trials process. It was fascinating to be part of the rigorous discussion around each candidate drug that involves not only the committee but PwP and

funding advisors. Understanding the process has been important given the number iLCT projects we evaluate a year within the research committee business.

We were also delighted that we recruited two new members to the research committee:

Dr Heather Mortiboys is Senior Lecturer/Senior Research Fellow at Sheffield University. Her research focuses on both trying to further the understanding of the causes of mitochondrial problems in neurodegenerative conditions and in vitro drug screening for molecules which rescue mitochondrial function in patient tissue. The repurposed drug, UDCA, came from this process. Heather said:

"It is an honour to join the research committee at CPT. I am very much looking forward to contributing to CPT's goal of accelerating research for a cure."

Originally a biochemist, Dr Kevin McFarthing spent most of his career leading R&D groups in life sciences. Diagnosed with Parkinson's in 2012, he now runs the Innovation Fixer consultancy and created the Hope List, a database of current therapies in development for Parkinson's. Kevin said:

"I'm delighted to join the research committee of The Cure Parkinson's Trust and to be able to make a small contribution to the search for a cure."

In 2019 CPT's research committee recommended a number of pre-clinical and clinical projects, several of which were related to the iLCT programme.

These included:

1. An imaging sub-study of the exenatide phase III trial that has now started in the UK.
2. A study using wearables to provide additional data from participants in the exenatide phase III trial.
3. A project to test drugs to reduce the build-up of alpha synuclein in pluripotent stem cells that have a "triplication" of the α -synuclein gene.
4. A trial of the immunosuppressive medication azathioprine that will get underway in 2020.
5. A sub-study within the nortriptyline trial to gather evidence of possible neuroprotection.
6. A clinical trial of the liver drug UDCA that preclinically shows evidence of improving mitochondrial function in models of Parkinson's.
7. An online genetic testing study called PD Frontline to identify people to take part in the clinical trials of drugs such as ambroxol that may treat genetic forms of Parkinson's.



Prof. Alasdair Coles (left) and Dr Kevin McFarthing (right) at the annual iLCT committee meeting at VAI in Grand Rapids

RESEARCH UPDATE: GDNF

In the light of last year's GDNF trial results, CPT believed it was important to bring together all the teams internationally that have worked with neurotrophic factors over the last 25 years to better understand how to take this therapy and related compounds forward for the benefit of PwP.

In August CPT organised a meeting of experts with direct knowledge and practical experience in the field of neurotrophic factors, of which GDNF is one, with the intention of identifying and agreeing what is known pre-clinically and clinically and what still needs further investigation. It is from consensus and a strong scientific basis that we will be able to find a pathway forward.

The meeting hosted by Van Andel Institute was chaired by Professor Roger Barker who had undertaken a similar invaluable exercise in the field of stem cell research. In addition to the scientific experts, we were joined by key Parkinson's funding agencies: Michael J Fox Foundation; Parkinson's UK and NIH. Bristol trial participant Eros Bresolin and CPT trustee, Lyndsey Isaacs also attended the meeting.

There were presentations from a number of groups; one discussed the pre-clinical evidence that GDNF can rescue the nigrostriatal pathway; another presented on the 'lived' experience of the trial and a team that had driven all the clinical efforts also presented. There were discussions led by teams from gene therapy trials, and the meeting also focused on the current GDNF trials as well as the importance of patient selection, imaging and outcomes when considering future approaches.

Collectively, the meeting discussed the issues and agreed that further work is needed to understand what can be achieved with GDNF in the clinic to improve the lives of PwP. The findings of this meeting and these key

research questions are discussed in an up coming paper in The Journal of Parkinson's Disease.

One of the challenges we face with clinical trials is that we have no long-term, home based measures of Parkinson's that can detect the subtle changes we would hope to see in disease-modifying trials. This is an area CPT is working to address.

As a result of the recent Bristol trial, a new composite scale has been developed that uses clinical scores but re-evaluates them placing more emphasis on activities of daily living, and good quality ON time. Called PD-CORE, CPT surveyed more than 200 people with Parkinson's to identify a time value for a meaningful increase in ON time to include in the scale. These findings are being published in the journal Brain Communications.

Similarly, CPT is supporting PD-SENSORS, a study implementing the technology of the SPHERE House and platform in Bristol to develop outcome measures to objectively assess Parkinson's at home. This has the potential to transform the outcomes embraced in future trials and will help to capture scientifically any benefit so often eloquently reported by participants.

We are also delighted to report that the BBC2 documentary *The Parkinson's Drug Trial: A Miracle Cure?* which followed nine participants in the trial has deservedly won two prestigious awards: a Grierson Award and a National Television Award.

Apply for funding

The Cure Parkinson's Trust funds and facilitates laboratory and clinical research projects with the potential to cure Parkinson's, with urgency for people currently living with the condition.

We accept funding applications which may lead to:

- **Disease-modification (slow, stop, reverse)**
- **Translation into clinic (eg. phase 2b trial), typically within 5 years**

We DO NOT accept projects which focus only on symptomatic aspects of Parkinson's.

We are a member of the Association of Medical Research Charities (AMRC). AMRC charities must follow rigorous peer review processes to ensure that only research of the highest quality is supported.

We welcome enquiries from researchers who seek clarification on the suitability of projects for funding by CPT.

In March 2019, we hosted a meeting of experts to review CPT's research strategy (as summarised above), to ensure it remains relevant, clear and resonant. The experts assembled confirmed this: CPT's strategy is both innovative and fit-for-purpose. A priority is to support clinical trials, but CPT is not restricted to clinical trial-related work. We will consider funding for other important promising (laboratory and non-clinical) research which has potential to lead to a cure for Parkinson's.

*More widely, our aim to cure (slow, stop and/or reverse) can include prevention or delay to onset, although **our priority remains to cure those living with Parkinson's now.***

For full details of our funding criteria and details of how to apply, please visit www.cureparkinsons.org.uk/applyfunding

Following the yellow brick road to success... *for a cure*

In the 'Wizard of Oz', Dorothy and her dog Toto start off on a long journey to find success, and success for them meant finding the wizard who lives in the Emerald City. There are many twists and turns and interesting characters along the way, but they do get there, they do find the wizard.

Peter Berners-Price, CPT Trustee since 2006, looks back at 15 years of The Cure Parkinson's Trust.



Success for us is finding a cure for Parkinson's, and our journey started in 2003 when the four co-founders of The Cure Parkinson's Trust met for the first time, not actually on the yellow brick road, but on the Millennium Bridge. That was where the late Tom Isaacs arrived in London at the completion of Coastin', his year-long 4500 mile walk around the coastline of Great Britain. All four co-founders, Sir Richard Nichols, Air Vice Marshal Mike Dicken, Sir David Jones and Tom were living with Parkinson's and all four dared to believe that a cure for Parkinson's could be found. However, they realised that would only happen if there was a more direct focus brought to bear on research... there needed to be a revolution!



Tom Isaacs on the Millennium Bridge, London at the end of his Coastin' challenge

2005: The creation of The Cure Parkinson's Trust (CPT).

The impact of this ground-breaking decision, to create a completely new charity, stimulated a significant change in the approach to Parkinson's research. As a result, this is now better mapped, receives more investment, fosters global co-operation and has already led to new research into treatments that could change the course of the condition forever.

2009: Research initiated into exenatide opened up a whole new and promising field of research in Parkinson's... in fact a completely new gateway towards a cure.

As also reported on page 4, pre-clinical evidence had suggested that exenatide, a drug already in use in the treatment of type II diabetes, might also be effective in the treatment of Parkinson's. CPT funded the initial trial, and the findings of that study were encouraging enough to set in motion a second, placebo-controlled trial. As evidence of the global co-operation facilitated by CPT, this trial was funded by the Michael J Fox Foundation.

The positive outcome of this research into exenatide led our research team to the exciting realisation there were potentially a number of other drugs already in use in other treatments that could quite possibly be

repurposed to change the progression of Parkinson's. As these drugs had already passed regulatory tests they could be brought to clinic far more quickly.

Parallel trials with drugs in the same category as exenatide such as liraglutide and lixisenatide were then designed and funded by CPT, and exenatide is now in a Phase III clinical trial in the UK which CPT is supporting. Again as a result of CPT's influence, pharmaceutical companies Neuraly and Peptron have also recently started trials in Parkinson's with their own exenatide-like drugs.

2012: The impact of these new trials inspired the foundation of the International Linked Clinical Trials programme (iLCT).

The iLCT programme has now grown from a compelling idea to a world-renowned clinical trial programme for disease modification. Its momentum has been inspired by collaboration between research experts, funders and people living with Parkinson's from around the world. All have come together with the aim of curing Parkinson's. We are co-funding this extensive programme of clinical trials with the support of VAI in the US, and we are influencing governments to invest in trials of disease-modifying drugs for Parkinson's as demonstrated through the Australian Parkinson's Mission programme.

Earlier this spring, we gathered those who had been involved with the charity since its inception. In January, Sir David Jones passed away and it is up to us now to deliver the vision of all four co-founders who are sadly no longer with us. Marking 15 years of success and determination, pictured left to right are: Shelagh Nichols, Dr Richard Wyse, Jenny Dicken, Peter Berners-Price, Helen Matthews and Lyndsey Isaacs



2014: The first *Rallying to the Challenge* meeting was held as part of the *Grand Challenges in Parkinson's Conference* at VAI.

Our determination to involve PwP in research design and trial delivery has underpinned the ethos of CPT since the very beginning. *Rallying*, first inspired by Tom Isaacs is a great and practical example of this.

This annual PwP-led conference involves workshops and think-tanks. It is designed to challenge barriers that may still be holding up or hampering research, and it also identifies how PwP can more actively

support research. The result of this initiative is that we work ever more closely with PwP and researchers worldwide to design and shape clinical trials, ensuring that they are relevant and deliverable.

2019: CPT funds research focussed on building 'trial ready' cohorts of PwP that can speed up the implementation of the iLCT programme.

Identifying PwP with certain disease characteristics will enable more targeted and personalised clinical trials going forward. For example, the Rapsodi and Frontline projects are seeking those with genetic risk factors. As a result, the iLCT programme now includes a focus on a more targeted approach for specific types of Parkinson's. For example, the ambroxol trial involved a cohort with GBA Parkinson's.

2020: Our 15th Anniversary and preparing for the future.

Looking to the future, we can already see that Parkinson's research is gathering speed in many **new directions**.

These will involve **dual therapies** that target multiple mechanisms of action, more complex clinical trial designs such as **multi-arm studies**, incorporating more seamless transition between phases and also the **exploration of treating Parkinson's before symptoms actually appear, during the 'prodromal' period**.

We are already taking constructive actions on these new directions, for example by supporting the Australian Parkinson's Mission with their multi-arm clinical trials, and extending the scope of the iLCT programme with fantastic support from VAI.

Our journey continues, and we now have so many travelling companions that give us such great encouragement to continue firmly along the path we started 15 years ago. But the pathway has changed - from just walking along the yellow brick road, we are now speeding along the multi-coloured, multi-dimensional highway!

Our goal in 2005 was to render our charity redundant. We know that the process of finding a cure is taking longer than we may originally have hoped. Nevertheless, this is still our goal, and the revolution that began it all 15 years ago has now morphed into a well-considered, well-supported and well-directed evolution. Like Dorothy, we **will** get there!



Parkinson's Advocates at the very first Rallying to the Challenge in 2014

To find out more about our 15th anniversary, please visit www.cureparkinsons.org.uk/News/cpt-15years

Get involved *for a cure*

2019 was a year of international meetings with *World Parkinson Congress (WPC)* in June and *Rallying to the Challenge* in August. CPT was delighted to support a team of Parkinson's Movement (PM) advocates as delegates at *World Parkinson Congress* in Kyoto – the triennial conference that unites research with people living with Parkinson's and health care professionals.

In June 2019, CPT staff and advocates travelled to Kyoto for *WPC*. The team were involved in contributing to the conference on many levels from speaking to presenting posters, from being panellists to leading round tables and producing Music Night. CPT trustee Lyndsey Isaacs spoke powerfully at the Opening Ceremony and PM advocate Soania Mathur was presented with the 'Distinguished Contribution to the Parkinson Community' award, nominated by both Parkinson's Movement's Eros Bresolin and CPT's Helen Matthews. The next *WPC* will take place in Barcelona in 2022.



CPT advocates Tom Gisby (left), Joy Milne (centre) and Vicki Dillon (right) at *WPC* 2019 Kyoto

Working in collaboration with the Michael J Fox Foundation for Parkinson's Research, Parkinson's Foundation and Parkinson's UK, CPT co-hosted a series of discussion-led sessions in the Clinical Research Village, which explored the ins and outs of participating in clinical trials. Each panel comprised a mix of trial volunteers and researchers and generated thoughtful debate and insights.

This year's *Rallying to the Challenge* meeting, once again generously hosted by Van Andel Institute focused on genetics. Team Spark from Grand Rapids presented the findings of a survey exploring misconceptions around genes and the types of genetic testing. Ralliers debated the ethical conundrum around genetic heredity, the importance of genetic counselling and there was a lively debate on the subject of *'This house believes that increased knowledge about genetics will muddy the water not clear the air'*.

These were timely discussions as research is escalating into potential treatments targeted at genetic forms of the condition. Now there is an urgent need for genetic testing.

In 2020 the theme is *When and How does Parkinson's Start?* and we envisage another lively year exploring



Dan and Ginny DeWitt representing Team Spark.

the themes of environmental factors, lifestyle factors and furthering these discussions around genetics.

CPT would like to thank Team Spark and VAI for their partnership in creating and hosting the annual *Rallying* meeting.

**Rallying to the Challenge 2020:
23-24 September at VAI, Grand Rapids, Michigan
'When and How Does Parkinson's Start?'**

Parkinson's webinar series

In 2018, we launched our quarterly Parkinson's webinar series, in collaboration with *The Journal of Parkinson's Disease (JoPD)* and Parkinson's Movement.

The webinar panel, chaired by *JoPD* Editor-in-Chief Professor Patrik Brundin, comprises clinical and pre-clinical expertise from world-leading researchers, as well as expert views from people with Parkinson's with an interest in the webinar theme.

"As our understanding of Parkinson's continues to evolve, these webinars serve as a great way to engage with the Parkinson's community on emerging topics that directly impact their daily lives."

Professor Patrik Brundin

The series has covered a range of engaging topics related to Parkinson's including exercise, dyskinesia, stem cell research and sleep. The webinars continue to be a great success reaching a global audience of more than 4,000 viewers over the past year.

"The model of involving the patient voice so clearly in the process encourages patients to feel more open to asking questions, to work at understanding research, and to feel like they have an opportunity to affect change in research that may have effect on their own course of Parkinson's. For researchers, it increases the probability that their research will be relevant in the lives of people living with Parkinson's."

Karen Raphael, Patient Advocate

Following recording, the webinars are available to watch again on at www.cureparkinsons.org.uk/webinars



"I believe in patient empowerment. The webinar is an excellent platform to share knowledge and experience to others. In my opinion educating the Parkinson's community can increase wellness."

Martin Taylor, a Parkinson's research advocate from Scotland, took part as a PwP panellist in the dyskinesia webinar in October last year.

The Tom Isaacs Award



Nominations are now open for the 2020 Tom Isaacs Award

The Tom Isaacs Award is presented annually by CPT and Van Andel Institute to a researcher who has shown the greatest impact on the lives of people living with Parkinson's and/or has involved people with Parkinson's in a participatory way in their work.

In 2019, Dr Tilo Kunath, a leading stem cell researcher, was the recipient. His empathy and enthusiastic engagement with the Parkinson's community and his willingness to share his expert research knowledge particularly impressed both those who nominated him and the panel of judges.

CPT's Deputy CEO, Helen Matthews, said:

"This award is hugely deserved. Tilo embodies the spirit of the award. He inspires the Parkinson's community in Scotland and his proactive approach of involving people living with Parkinson's with research, listening to the community to inform research is exemplary."

Pictured above: Dr Tilo Kunath (right) with the CPT co-founder the late Tom Isaacs (left)

To nominate, please visit www.cureparkinsons.org.uk/TI-award-recipients

The closing date for nominations is 1 August 2020

2019 *for a cure*

2019 was a memorable year with some fantastic research and fundraising events. Thank you to everyone who attended or participated.

You can find out more about future events, by visiting our website at www.cureparkinsons.org.uk/events

February 2019



At the end of February the results of the GDNF trial were published in *Brain* and *The Journal of Parkinson's Disease*. BBC documentary *The Parkinson's Drug Trial: A Miracle Cure* aired shortly after and followed the trial and nine of its participants including CPT co-founder, the late Tom Isaacs. You can read more about the GDNF trial on page 7.

April 2019



On 11 April, we were delighted to announce Tim Daber (pictured centre) as CPT's 2018 Fundraiser of the Year. Tim raised over £76,000 for CPT after a year of fundraising which culminated in a 64 mile walk around the north Norfolk coastline. Read about our recently announced 2019 award winner on page 18.

April 2019



Our Spring Research Update Meeting took place in Cambridge on World Parkinson's Day. Presenting were world renowned Parkinson's stem cell researchers including Jun Takahashi (pictured) from Kyoto University and Malin Parmar from Lund University. To view their talks and others from the meeting, visit www.cureparkinsons.org.uk/News/g-force-pd-and-update

May 2019



The annual Gulls' Eggs Luncheon for the wealth management sector took place at Merchant Taylors' Hall. Pictured above are CPT patrons, Joanna Trollope CBE and Robert Voss CBE, the Lord-Lieutenant of Hertfordshire with Rupert Phelps, Chair of the Gulls' Eggs Committee and Will Cook, CPT CEO.

May 2019



CPT's longest running event, the annual Bluebell Picnic, took place in May at Hedsor Park. CPT would like to thank supporters Janey and Alexander Shephard and CPT patron Jenny Dicken for hosting and organising this popular event for so many years. Sadly, the 2020 Bluebell Picnic is cancelled however, we hope that it will return next year.

June 2019



In June, our AEGIS Coast to Coast to Cure challenge team took on the Raid Pyrenean. 13 CPT supporters including CPT Patron Mike Tindall MBE and fellow Rugby World Cup winner Iain Balshaw MBE took on this extreme cycle through the French Pyrenees covering 735km to raise vital funds for CPT research.

August 2019



The Tom Isaacs Award was presented to Dr Tilo Kunath who was nominated by Joy Milne (pictured above). She inspired Dr Kunath's research into the aroma of Parkinson's. A great example of listening and involving people affected by Parkinson's in research. To read more, please visit www.cureparkinsons.org.uk/ti-award-tk-2019

October 2019



The annual Grouse & Grape Luncheon was held in October at the historic Spencer House, and attracted 300 guests. For the fourth year running, the Luncheon was generously supported by Headline Sponsor CRUX Asset Management. The luncheon is a unique networking event which has developed a loyal following since its inception nine years ago.

August 2019



The International Linked Clinical Trials and *Rallying to the Challenge* meetings took place in August at Van Andel Institute, Grand Rapids, Michigan. These meetings are key events in CPT's research calendar which bring together experts from the Parkinson's community to share knowledge and experience.

October 2019



The Tom Isaacs Charity Golf Day at Denham Golf Club is always a highlight in CPT's event calendar. In 2019, 76 players enjoyed a round of golf in memory of CPT's late co-founder, Tom Isaacs with 19 teams of players competing for the Tom Isaacs 'inspirational' trophy which was kindly donated by 'The South Bank Surveyors' team.

October 2019



CPT's Autumn Research Update Meeting at Deloitte was as popular as ever. The audience heard talks from Professors Tom Foltynie, Anette Schrag, Dr Stephen Mullin and CPT's Dr Simon Stott. To listen to the presentations please visit, www.cureparkinsons.org.uk/News/autumn-research-meeting-2019

Raising the Funds... *for a cure*

Rick Lay, CPT Director of Fundraising & Marketing



When I sat down to watch a documentary about Parkinson's in February 2019, I had no idea of the impact it would have on me. I cried, I laughed but most importantly I felt a sense of hope. Before the first episode had finished, I'd emailed The Cure Parkinson's Trust to ask how I could get involved.

On 1 July 2019 I joined the charity as Director of Fundraising & Marketing, this is a role that combines personal interests (I was diagnosed with Parkinson's in 2017) and my professional fundraising experience.

The hope for a cure that was sparked whilst watching Tom and 41 trial volunteers has been constantly reinforced by the boundless commitment and energy shown by the charity's fundraisers and supporters, right across the UK.

Throughout 2019 we have benefited from long-standing and new relationships. You can read about some of our fantastic fundraisers on pages 16 and 17. We are also grateful to have had support from charitable trusts and from the business community.

Our fantastic supporters have arrived at the office weighed down with collection tins, set-up Facebook fundraisers, sent cheques, made regular gifts, or remembered us in their wills. We have also benefitted from the sweat of people that have run or cycled for

the charity as well from the thousands of people that have attended a CPT event.

When I first wrote this introduction, I had never heard of COVID-19. And yet, in a few short weeks this awful virus has transformed the way we all live. Inevitably, CPT's 2020 fundraising plans have changed beyond all recognition. We have adopted new ways of working and are focused on minimising the impact on our vital research. However, this will be a challenging year for the charity. If you are able, your support of the charity will count for more than ever.



The Grouse & Grape Luncheon committee pictured here at Spencer House, London. This annual city networking event raises vital funds for CPT.

We will reschedule as many of our events as possible and you can keep up to date with our plans via our monthly e-news. You can sign up online at www.cureparkinsons.org.uk/forms/permissions.

Looking ahead I am focused on laying the foundations to deliver additional income to the charity. This work is taking place against a backdrop of economic uncertainty and changes in the way people support charities. As an organisation that receives no statutory funding it is vital that we have a broad base of sustainable fundraising activities in place, to underpin our work in finding a cure for Parkinson's.

If you are able to make a donation, please complete and return the donation form attached to this annual review. Or call the team directly on call 020 7487 3892.

If you would like to take on a challenge or organise an event to raise money for CPT please contact Leanne at leanne@cureparkinsons.org.uk or call 020 7487 3892.

Your support, in whatever shape it takes was and will continue to be received with heartfelt thanks.

Take on the challenge... *for a cure*

You can join our amazing team of supporters taking on a challenge event to raise awareness and funds for The Cure Parkinson's Trust. Whether you love cycling, want to take up running or are a keen swimmer, we've got something for you. You can even take part in your own time and at your own pace!

2020 Challenges



Linked Cycle Trails



This September, we need your pedal power to help raise vital funds for our International Linked Clinical Trials Programme and help fast-track our research.

The Linked Cycle Trails campaign gives you the chance to get creative and enjoy the great outdoors whilst supporting CPT. Get together with friends, family or colleagues and choose one of the many fantastic cycling events taking place in the UK, Europe, or around the world this September. You can even organise your own cycling event; decide your route, choose your distance and recruit some fellow cyclists to join you on the trail. You could even take part on a static bike indoors – everyone loves a Spinathon!

To find out more and for information on how to organise your own event, contact Jess at jess@cureparkinsons.org.uk or call 020 7487 3892

Positively Parkinson's Challenge



In September, a team of 12 swimmers, comprising people with Parkinson's together with their family and friends, will take up the Positively Parkinson's Challenge to swim from Gosport to Ryde on the Isle of Wight.

Vicky Knight and Peter Burns (pictured) created the Solent Swim challenge to raise awareness and help people with Parkinson's adjust to life after their diagnosis with a positive mindset. You can join in the campaign by taking part in a pool based 5K Challenge in your own time at your own pace, from 1-30 September 2020. This is open to all swimmers who can match the Solent swim distance – or 200 lengths of a 25m pool – and raise funds for CPT.

To find out more and for information on how to get involved in the 5K pool challenge, contact Leanne at leanne@cureparkinsons.org.uk or call 020 7487 3892

It's never been so easy to sign up to a challenge event to raise funds and fast-track our quest to find a cure for Parkinson's. Here's how you can get involved:

1. Find your challenge. Visit our website for some ideas, or why not create your own like Vicky and Peter – keep it easy if you're just starting out, or push yourself further than ever before!
2. Tell us about your challenge. We're here to support you and can send fundraising tools to help you reach your goals.
3. Set up your online fundraising page and tell all of your friends and family about your challenge.
4. Get training and fundraising!

To sign up for a challenge, please contact the Fundraising Team at events@cureparkinsons.org.uk or call 020 7487 3892

Above, beyond and around the world ... *for a cure*

The Fundraiser of the Year Award recognises an individual who has gone to extraordinary lengths to raise funds and/or awareness for Parkinson's. **Maura Ward** has not only raised an incredible amount for CPT, but with press coverage in local and national Irish newspapers, and even a video interview with the BBC, Maura has gone above and beyond to raise awareness of the condition too.



Maura Ward from Kilkeel, Northern Ireland, was diagnosed with Parkinson's in 2013 aged 64. In July 2019, to mark her 70th birthday, she took on the incredible challenge of climbing the 12,389 ft high Mount Fuji in Japan. Along with her son Johnny who helped organise the climb and supported her every step of the way, Maura raised an amazing £14,574 for CPT.

Even before her training was curtailed by illness in the months leading up to the challenge, Maura knew this would not be an easy feat. The altitude sickness Maura was dreading crept in not long after she had begun her ascent, which resulted in dizziness, lack of oxygen and the sudden worsening of her Parkinson's symptoms. Towards the end of the first day, a particularly challenging section lasting three hours reminded Maura that Fuji was in fact a volcano as they scrambled up the extremely steep volcanic rock on their hands and knees. Eventually they reached their designated rest stop, where the other 17 members of the team were waiting to hug and cheer for Maura when she arrived.

Day two was no easier. Maura continued to struggle with altitude, which in turn affected her balance, her breathing and her strength. Johnny worried that they may need to stop before reaching the top. Maura's relentless determination, however, ensured she

slowly put one foot in front of the other until at 10am on 10 July, Maura and Johnny reached the top of Mount Fuji. They purchased postcards to send home, on which Maura managed to scribble 'Made it!'

"Strangely, at no time on the climb did I even consider giving up, it simply wasn't an option. Prior to coming to Japan, friends kept telling me not to overdo it, that all the donors would understand and accept my being unable to finish, to just do my best. But people whom I know could ill afford to give me donations, and I felt I would be letting all the donors, but those people in particular, down," said Maura.



Maura Ward and her son Johnny at the summit of Mount Fuji

"The climbing group, mostly strangers before this, but dear friends now, got me through it. Their kindness, care and warmth still reduces me to tears when I think about it."

Maura also kept her followers updated on her blog, *Geriatric Traveller*, which she started soon after her diagnosis as she decided to pursue her dream of travelling. Maura has now visited over 60 countries and counting!

"I still haven't entirely come to terms with the enormity of the whole experience, but in time I will. If my struggling up Fuji helps a single soul with Parkinson's come to terms with their diagnosis, or it shows even one person that a Parkinson's diagnosis doesn't mean the end of everything, then it was worth every painful step."

CPT CEO Will Cook says,

"Maura is an inspiration. Not only has she completed this gruelling climb to the top of Mt Fuji, but she has harnessed an incredible network of supporters through her personal contacts, media interviews and her blog which translated into a huge sum raised for the search into a cure. Maura says that this was a team effort, and our thanks go to all those who walked and fundraised with Maura, especially her son Johnny. But we are delighted to recognise Maura for her excellent achievement at the heart of this challenge."

Feeling Inspired?

Why not do your own fundraising for CPT and every pound you raise will help us fund research to slow, stop and reverse Parkinson's.

Quiz for a Cure

Host a quiz at your local pub, church hall or even completely virtually from your own living room! Why not include a round on Parkinson's science to really test the teams?

Walk for a Cure

A sponsored walk is a simple and fun way of raising some money and getting the whole family stuck in. Plan your own route and get a whole team to walk together!

Captains for a Cure

Tee off to raise funds for The Cure Parkinson's Trust with a charity golf day. You could host a dinner to round off your day and organise a silent auction or raffle.

Celebrations for a Cure

Raising money at your birthday event or wedding can make a huge difference. Why not set up an easy Facebook birthday fundraiser to start collecting donations?

For more information and fundraising ideas, please contact the Fundraising Team at events@cureparkinsons.org.uk or call 020 7487 3892

We would also like to say thank you to two very impressive runners-up. Martin Wishart and John MacPhee who organised their own incredible challenges in 2019 raised significant funds for The Cure Parkinson's Trust.



Michelin Star Chef Martin Wishart sailed across the Atlantic in November 2019 to raise funds and awareness for CPT. For just over a month Martin left his Edinburgh restaurant behind to set sail from Portugal and make the crossing towards St Lucia. As well as raising an incredible sum, Martin worked extremely hard to raise awareness of CPT and of Parkinson's.

"It truly was a real honour to support CPT through the Atlantic crossing fundraiser. I really do have a lot of people to thank for supporting the fundraiser and myself, especially my wife Cécile, my family and of course the fabulous crew; without them none of this would have happened."



In June 2019, John MacPhee and his aptly-named 'Parkinson's Power' team took on an incredible endurance cycle challenge in support of CPT. As part of the WOW Cyclothon, John and the team cycled 1358km around the entire border of Iceland in just 56 hours, 57 minutes!

"The Parkinson's Power Team's Icelandic adventure was quite simply one of the most challenging but rewarding things I have ever been involved in."

You can read more about Maura, Martin and John by visiting our website at www.cureparkinsons.org.uk/fundraising-award

Attend an event... *for a cure*

Every year The Cure Parkinson's Trust hosts and is supported by a variety of wonderful events, from business luncheons to golf days. Due to the extraordinary situation concerning Coronavirus, we have made the difficult decision to either cancel or postpone some of our most-loved events. We want to thank everyone involved in these events for their incredible support and promise that the events will return, bigger and better than ever before. Together, we will find a cure for Parkinson's.

We know that the cancellation or postponement of our events will be a huge disappointment to everyone involved; the committees who have donated their time and incredible efforts to plan and deliver these wonderful events, our extremely generous sponsors and their teams, and everyone who had bought a ticket to support the work of CPT. Thank you all for your understanding and support.

The health and wellbeing of anyone due to volunteer or attend the events is our overriding priority at this time.

However, these events are vital to CPT; anyone who has ever supported us by buying a ticket, participating in a raffle or by volunteering their time have helped to raise funds and facilitated significant investment into Parkinson's research. We can't find a cure without you.

We are hugely optimistic that many of our events will be back in autumn 2020 or spring 2021, and hope you will be there to join us.

Please visit our website for further updates, including information on new event dates and how to book your place. Alternatively, contact the Events Team at events@cureparkinsons.org.uk or call 020 7487 3892.

The Grouse & Grape Luncheon



Ceres Race Day



The Tom Isaacs Charity Golf Day



The Bluebell Picnic



The Gulls' Eggs Luncheon



Hilton Food Groups Golf Day



Legacies... *for a cure*

Gifts in wills help us to plan and deliver more research projects for the future, bringing the Parkinson's community closer to the day where they will have access to a drug that can slow, stop or reverse this terrible condition. We are very grateful for every single gift that we receive. Anything you choose to leave in your will could make a significant difference to the future of those living with Parkinson's.

By leaving a gift in your will, you are laying the foundations for future research projects. No matter how much you choose to leave as a legacy, you can rest assured that we'll spend your money wisely, single-mindedly funding the best curative research projects available. But don't just take our word for it...

"As an ambassador for CPT and someone who is living with Parkinson's, I wanted to thank you for taking the time to consider leaving a gift in your will. I know that gifts in wills are a personal matter, and it's important that you take care of your family and friends first. Your gift will help fund some of the world's top Parkinson's scientists, helping to deliver the research that will lead to treatments that slow, stop or reverse Parkinson's and for all of us living with Parkinson's, that day cannot come soon enough!"

Penny Kustow



If you're not sure which is best for you, here are the most common types of gifts our supporters choose from.

A share of your estate

Once you have taken care of your loved ones, you can leave a share, or the remainder, of your estate to us. This is called a residuary gift.

A gift of money in your will

You can choose to leave us a specific amount of money in your will. This is called a pecuniary gift.

A specific gift in your will

You can choose to leave us a specific item, such as jewellery, works of art or even a house when making a Will. This is called a specific gift.

A gift when a trust ends

You might want to set up a trust in your will so that someone can enjoy the benefit of some money or property during their lifetime. Afterwards, the remaining money or property would then come to us. This is called a reversionary gift.

If you are interested in leaving a gift in your will to CPT, please visit
www.cureparkinsons.org.uk/leave-a-legacy

Our promise to you

We understand that loved ones always come first.

Your will is personal and we'll never ask you to tell us your decision, although we would love the opportunity to say thank you and will always be happy to answer any questions you have about our work.

We'll never put you under any pressure – it's your decision to make in your own time.

If you choose to remember us in your will, we'll use your gift carefully so it achieves the greatest impact for those affected by Parkinson's.

You can change your mind about leaving a gift at any time and we'll respect your decision.

Any personal information that you choose to give us will be handled securely and confidentially.

For more information, please contact Leanne at leanne@cureparkinsons.org.uk or call 020 7487 3892

Trusts, foundations and corporates, together... *for a cure*

Many of our trust and corporate supporters have been involved since the very early days of the charity and we are truly grateful for their ongoing support. In the last 12 months, we have also been exploring exciting opportunities with new organisations and partners, as this area of fundraising continues to grow.



Our trust and foundation partners have made a substantial impact to our work, making it possible for us to support more research projects which have the potential to slow, stop or reverse Parkinson's. By providing multiple year funding, our trust partners enable us to strategically plan for the future.

The Frank Brake Charitable Trust is an example of one such trust who has supported us annually for a number of years.

"The Frank Brake Charitable Trust has been supporting CPT since 2006. A number of our trustees have been personally affected by the impact of Parkinson's and we feel it is important to support work to help find a cure for this debilitating condition. In the last few years, we have been partnering with CPT to fund specific projects and most recently we were delighted to provide a donation to support the Imaging sub study for the Bydureon phase III trial."

Steph Senior, Chair of the Frank Brake Charitable Trust

To find out more about supporting CPT through a trust or foundation, please contact Simon at simon.green@cureparkinsons.org.uk or call 020 7487 3892.

Companies support us in so many ways: some fundraise for us, some sponsor or take part in our events or challenges, some create and run their own events while others donate auction prizes or even office space for events and meetings.

Since 2016, we have been selected as the annual beneficiary of the Gulls' Eggs and Grouse & Grape Luncheons. These incredible volunteer committees work so hard to fundraise on our behalf; they have already raised half a million pounds for CPT, which is a real reflection of their commitment.

We love working with our corporate supporters, helping them to fundraise for us in the many different and inspiring ways their teams choose to support us.

We would be thrilled to hear from you if you work for an organisation who select a 'Charity of the Year' or you are looking to develop a long-term charity partnership. Alternatively, perhaps your company could support us by attending or sponsoring our events.

"CPT was the obvious choice when AEGIS London decided to support a Parkinson's charity; we loved the no-nonsense determined intent of its title "Cure". Sponsoring the Raid Pyrenean gave us the opportunity to involve and inspire the wider London Insurance market with launch and wrap-up presentations 45

floors above ground-level and three floors below. By presenting a fresh take on this fascinating disease, promoting the Trust's progress in fighting it, and listening to Mike Tindall's and Iain Balshaw's rugby and cycling experiences we were proud when our market added significant contributions of their own. We know we are making a difference and have thoroughly enjoyed our first year of participation."

Simon Cooper, Aegis



Simon Cooper, AEGIS (left) pictured here with CPT CEO Will Cook (right)

To find out more about supporting CPT through a corporate partnership, please contact Julia at julia@cureparkinsons.org.uk or call 020 7487 3892.



Pictured above: Chairman of the Cure Collective,
Christopher Moger QC

In 2018 we launched the Cure Collective, a philanthropy circle that offers like-minded individuals the opportunity to come together to help drive forward our quest to find a cure for Parkinson's.

Over the last two years, Cure Collective members have committed over £600,000 to our research, specifically to our International Linked Clinical Trials (iLCT) programme. As we move into our 15th year at CPT, we are hoping to build on this success and create a £1 million pot that we are able to dedicate to this exciting research programme. We can achieve this with your support.

By asking members to commit at least £5,000 p.a. for a minimum of five years, we have a reliable income source that we can dedicate to this ground-breaking research which has already seen some promising results published.

"I am proud to be the chairman of the Cure Collective. This is an exciting initiative of CPT's that is committed to support CPT's ambitious and effective research programme. It is very encouraging to see, first hand, the impact that this programme is having on the international efforts being made to conquer this condition. A highlight for me is the annual Chairman's lunch, offering a lively and enjoyable opportunity to meet one another, but also an occasion at which excellent guest speakers from CPT's research committee have been able to respond authoritatively to issues raised by our Cure Collective members. I look forward to welcoming new and current members to this annual lunch next January."

Christopher Moger QC, Chairman of the Cure Collective.

Why join the Cure Collective?

Help us direct **£1 million** to support the iLCT programme

Be a part of our goal to make medical history

Have exclusive access to leading researchers at special events including the Chairman's annual research update lunch

Receive regular research updates in the Cure Collective quarterly newsletter

Philanthropic support

If you are in a position to make a larger one-off donation, we would be delighted to discuss with you details of our active projects and research programmes you might like to support.

CPT supporter Andrew wanted his donation to support a particular research project and chose to direct his donation to the ambroxol programme.

"My mother has Parkinson's and I've been a supporter of CPT for several years now. I was delighted to be able to make a large donation and I worked with the team to identify an exciting project where the money could make a real difference. I've been to a number of research meetings and have also been kept up to date by the team at CPT. I am keen to do as much as possible to find a cure for Parkinson's."

Andrew



Pictured above: Andrew and his mother Sue

If you would like to discuss making a gift of £5,000 or more, please contact Ella at ella@cureparkinsons.org.uk or call 020 7487 3892

Please get in touch with Ella at ella@cureparkinsons.org.uk if you would like to know more or are interested in committing your support.

Funding... *for a cure*

A good financial performance in 2019 has given us a solid base to invest in further ground-breaking research and clinical trials in 2020 and beyond. The challenge in 2020 is to maintain and build on this.

Total Income: £3,055,633
 Total Expenditure: £2,443,366
 Total spend on charitable activities:
 71.6p in every £1 is directed to CPT's charitable activities

Total income (including investment gains) in 2019 was £3.05mn, a result comparable to the previous year when we raised £3.06mn. Bearing in mind the 2018 figures included £500k raised at the Cure³ exhibition in October 2018, the 2019 figures are encouraging. They reflect the increasing breadth of our supporter base and the incredible generosity of donors and individuals who have undertaken fundraising events to raise funds.


In addition to the core donations from individual supporters in 2019 we also raised income from a wide range of partner-led fundraising events. These included the prestigious city-based networking events, the Gulls' Eggs Luncheon and the Grouse & Grape Luncheon. Additionally, we were the 2019 charity partner for the Worshipful Company of Butchers and our Patron, Mike Tindall's, Golf Day.

In 2019 we spent £1.75mn on charitable activities with our reserves at the end of the year increased by £0.6mn to £3.25mn. This now puts CPT in a strong financial position to continue work with funding partners to realise the iLCT trials referred to on pages 4 and 5 through 2020 and beyond.


All the money we raised has come from voluntary donations: the charity does not receive any statutory funding. All the charity's fundraising activities are managed in-house, by the charity's fundraising team.

CPT takes the responsibility to safeguard and make the best use of your donations very seriously with the financial controls and performance monitored closely by a Finance Committee, chaired by a Trustee and chartered accountant, which meets in advance of the quarterly meetings of the Board of Trustees. The Statutory Accounts for 2019 have been audited and carry an unqualified opinion from our auditors, Mercer & Hole, and will be publicly available from the beginning of May 2020.

Where did our funding support come from?



Where did we spend the funds?



Our audited accounts are available at www.charitycommission.gov.uk or directly from The Cure Parkinson's Trust by emailing cptinfo@cureparkinsons.org.uk

The Cure Parkinson's Trust would like to thank all the individuals and organisations that have supported us in 2019.

Thank you to our patrons, supporters, researchers, scientists, healthcare professionals, collaborators, regular givers, trusts, foundations, corporate supporters, corporate donors, individual fundraisers, key supporters, Parkinson's advocates, committees, members of Parkinson's Movement and our staff and volunteers...

With your support, we will find a cure!

Thank you!

Our donors can be assured that we comply with all regulatory standards for fundraising. We are registered with the Fundraising Regulator, are committed to the Fundraising Promise and adhere to the Code of Fundraising Practice. We did not receive any complaints about our fundraising activity during 2019. Our website outlines our complaints policy for the public and clearly explains how an individual can complain. We will respond to all complaints within 10 days. Complaints are dealt with in-line with our fundraising complaints policy. Serious complaints are escalated to our leadership team and trustees so they can consider lessons learnt. We report to the Fundraising Regulator on the totality of our complaints.

CPT has published its vulnerable person's policy on our website, and all fundraisers are familiarised with the policy to ensure that it is applied correctly. We are also signed up to the Fundraising Preference Service to enable individuals to opt out from receiving fundraising communications from us.

The Cure Parkinson's Trust is proud to be a member of the following organisations

amrc
ASSOCIATION OF MEDICAL RESEARCH CHARITIES

Registered with
FR FUNDRAISING
REGULATOR

The Cure Parkinson's Trust

The Cure Parkinson's Trust
120 New Cavendish Street
London W1W 6XX

T: + 44 (0)20 7487 3892

E: cptinfo@cureparkinsons.org.uk

www.cureparkinsons.org.uk

